Myriad Genetics has established a new $90 million asset-based credit facility with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, and the other lender parties thereto consisting of Wells Fargo Bank, N.A. and Bank of America, N.A. The ABL Facility includes an option to increase the maximum principal amount by up to $25 million for a total of $115 million. The ABL Facility replaces the Company’s previous credit facility and matures on June 30, 2026. The ABL Facility is secured by substantially all of the assets of Myriad Genetics and its subsidiaries. Additional details on the ABL Facility, including the interest rate on loans under the ABL Facility, are included in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 6, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
- Myriad Genetics assumed with an Underweight at JPMorgan
- Myriad Genetics enters research collaboration with MD Anderson
- Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
- Myriad Genetics to Participate in Goldman Sachs Healthcare Conference